<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02345005</url>
  </required_header>
  <id_info>
    <org_study_id>1060-011014</org_study_id>
    <nct_id>NCT02345005</nct_id>
  </id_info>
  <brief_title>Iliac Branch Excluder ReGistry (IceBERG)</brief_title>
  <acronym>IceBERG</acronym>
  <official_title>Multi-centre, Observational, Post-market, Real World Registry to Assess Outcomes of Patients Treated With the Gore® EXCLUDER® ILIAC BRANCH Endoprosthesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>W.L.Gore &amp; Associates</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rijnstate Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This post market registry consists of a retrospective and a prospective part. The first part
      is a retrospective registry of all implanted IBE devices of Gore in the Netherlands after CE
      mark was obtained, to get an initial insight on the feasibility and safety of this procedure.
      The second part is to prospectively register all data on implanted IBE Gore devices, in order
      to gain more robust data on the efficacy of the device in maintaining hypogastric artery
      patency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: The Gore IBE device is a newly designed iliac branched device, that is used in
      combination with the widely accepted C3 Excluder endograft for the exclusion of common iliac
      aneurysms and aorto-iliac aneurysms. The later has a proven safety and efficacy in excluding
      abdominal aortic aneurysms. The Gore IBE device got CE mark on October 2013. Technical and
      clinical data at short and long terms are still to be collected to give insight into
      technical success rates, patency data and long term follow-up.

      Objective and design: This investigator-initiated post market registry consists of a
      retrospective and a prospective part. The first part is a retrospective registry of all
      implanted IBE devices of Gore in the Netherlands after CE mark was obtained, to get an
      initial insight on the feasibility and safety of this procedure. The second part is to
      prospectively register all data on implanted IBE Gore devices, in order to gain more robust
      data on the efficacy of the device in maintaining hypogastric artery patency.

      Study population: All patients in whom a Gore IBE was or will be implanted. In the
      retrospective part of the study all implantations in the Netherlands will be gathered,
      whereas the prospective part will be expanded in Europe.

      Main study parameters/endpoints: Aneurysm exclusion and reinterventions will be end-points of
      this study. As safety and feasibility is the main outcome of the retrospective part, the data
      will be analyzed at 30-days. Patients in the prospective study will be followed for 5 years,
      with the primary end-point being hypogastric side branch patency at 1-year. Clinical
      endpoints include freedom from symptoms of pelvic ischemia (buttock claudication, impotence
      and bowel ischemia) and freedom from aneurysm rupture.

      Nature and extent of the burden and risks associated with participation, benefit and group
      relatedness: Since this is a registry study, no burden or risk exist for the patient. There
      is also no direct benefit for the participating patients, but the gathered data will improve
      insight for patients with the same disease and might improve health care in the future for
      this group of patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Immediate technical success</measure>
    <time_frame>Procedure</time_frame>
    <description>Primary endpoint of the retrospective part of the registry. Defined as successful implantation of the IBE device without the presence of endoleak type I or III and without flow-limiting dissection or stenosis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peri-operative and post-operative safety parameters</measure>
    <time_frame>Up to 30 days postprocedure</time_frame>
    <description>Primary endpoint of the retrospective part of the registry. Described as:
Mortality (all-cause; aneurysm-related, device-related)
Bowel Ischemia
Myocardial Infarction
Paraplegia
Renal Failure
Respiratory Failure
Stroke
Procedural Blood Loss ≥1,000mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary patency of hypogastric side branch</measure>
    <time_frame>At 1 year postprocedure</time_frame>
    <description>Primary endpoint of the prospective part of the registry. Defined as an open prothesis without flow-limiting stenosis (PSV&lt;2.5), successful exclusion of the aneurysm without type I or II endoleak.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anatomical success</measure>
    <time_frame>Measured at 1 month, 6 months, 1 year and then yearly up to 5 years</time_frame>
    <description>Secondary outcome of both parts of the registry. Defined as exclusion of the aneurysm without endoleak type I and III, and open stentgrafts on imaging without significant stenosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical endpoints</measure>
    <time_frame>Measured at 1 month, 6 months, 1 year and then yearly up to 5 years</time_frame>
    <description>Secondary outcome of both parts of the registry. Defined as:
Primary and primary-assisted patency of hypogastric side branch
Secondary patency of hypogastric artery
The presence of any endoleak
Freedom from aneurysm sac expansion and rupture
Device migration
Device occlusion
Conversion to open repair
Any secondary endovascular procedures, with special focus on Secondary endovascular procedures for resolution of: endoleak of any type, device occlusion (due to thrombus or other causes), device migration, abdominal aneurysm sac expansion, device defect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success</measure>
    <time_frame>Measured at 1 month, 6 months, 1 year and then yearly up to 5 years</time_frame>
    <description>Defined as freedom from flow-limiting stenosis and freedom from new onset of clinical ischemic symptoms (buttock claudication, erectile dysfunction, bowel ischaemia).</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Abdominal Aortic Aneurysms</condition>
  <condition>Common Iliac Aneurysms</condition>
  <condition>Aneurysm</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The Gore® EXCLUDER® ILIAC BRANCH Endoprosthesis.</intervention_name>
    <description>The Gore IBE device is a newly designed iliac branched device, that is used in combination with the widely accepted C3 Excluder endograft, for the exclusion of common iliac aneurysms and aorto-iliac aneurysms.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients in whom a Gore IBE was or will be implanted.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  Provided written informed consent for data release

          -  Elective procedure; Indication for aorto-iliac endovascular stent graft repair, as
             determined by the treating physician

        Exclusion Criteria:

          -  Patient is participating in another clinical study (RCT; interfering with endpoints)

          -  Patient's life expectancy &lt;2 years as judged by the investigator

          -  Patient has a psychiatric or other condition that may interfere with the study

          -  Patient has a known allergy to any device component (ePTFE, FEP, nitinol)

          -  Patients with a systemic infection who may be at increased risk of endovascular graft
             infection

          -  Patient has a coagulopathy or uncontrolled bleeding disorder

          -  Patient has a ruptured, leaking, or mycotic aneurysm

          -  Patient had a CVA or an MI within the prior three months

          -  Patient is pregnant (Female patients of childbearing potential only)

          -  Other stents placed in CIA or hypogastric arteries than the Gore® EXCLUDER® iliac
             branch Endoprosthesis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Reijnen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rijnstate Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven van Sterkenburg</last_name>
    <role>Study Director</role>
    <affiliation>Rijnstate Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daphne van der Veen</last_name>
    <phone>003188 005 72 82</phone>
    <email>vascularsurgery@rijnstate.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondazione Poliambulanza</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bellosta</last_name>
    </contact>
    <investigator>
      <last_name>Bellosta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardarelli Hospital</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruotolo</last_name>
    </contact>
    <investigator>
      <last_name>Ruotolo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Filippo Neri Hospital</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mangialardi</last_name>
    </contact>
    <investigator>
      <last_name>Mangialardi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <zip>6800 TA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Holewijn</last_name>
      <phone>003188 005 72 82</phone>
      <email>vascularsurgery@rijnstate.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elisabeth Hospital</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heyligers</last_name>
    </contact>
    <investigator>
      <last_name>Heyligers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holden</last_name>
    </contact>
    <investigator>
      <last_name>Holden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitelario Universitario de Ourense (CHUO)</name>
      <address>
        <city>Ourense</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mosquera</last_name>
    </contact>
    <investigator>
      <last_name>Mosquera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Casa de Salud</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gomez</last_name>
    </contact>
    <investigator>
      <last_name>Gomez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Blankensteijn JD, de Jong SE, Prinssen M, van der Ham AC, Buth J, van Sterkenburg SM, Verhagen HJ, Buskens E, Grobbee DE; Dutch Randomized Endovascular Aneurysm Management (DREAM) Trial Group. Two-year outcomes after conventional or endovascular repair of abdominal aortic aneurysms. N Engl J Med. 2005 Jun 9;352(23):2398-405.</citation>
    <PMID>15944424</PMID>
  </reference>
  <reference>
    <citation>EVAR trial participants. Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial. Lancet. 2005 Jun 25-Jul 1;365(9478):2179-86.</citation>
    <PMID>15978925</PMID>
  </reference>
  <reference>
    <citation>Prinssen M, Verhoeven EL, Buth J, Cuypers PW, van Sambeek MR, Balm R, Buskens E, Grobbee DE, Blankensteijn JD; Dutch Randomized Endovascular Aneurysm Management (DREAM)Trial Group. A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. N Engl J Med. 2004 Oct 14;351(16):1607-18.</citation>
    <PMID>15483279</PMID>
  </reference>
  <reference>
    <citation>Greenhalgh RM, Brown LC, Kwong GP, Powell JT, Thompson SG; EVAR trial participants. Comparison of endovascular aneurysm repair with open repair in patients with abdominal aortic aneurysm (EVAR trial 1), 30-day operative mortality results: randomised controlled trial. Lancet. 2004 Sep 4-10;364(9437):843-8.</citation>
    <PMID>15351191</PMID>
  </reference>
  <reference>
    <citation>Brunkwall J, Hauksson H, Bengtsson H, Bergqvist D, Takolander R, Bergentz SE. Solitary aneurysms of the iliac arterial system: an estimate of their frequency of occurrence. J Vasc Surg. 1989 Oct;10(4):381-4.</citation>
    <PMID>2795762</PMID>
  </reference>
  <reference>
    <citation>Richardson JW, Greenfield LJ. Natural history and management of iliac aneurysms. J Vasc Surg. 1988 Aug;8(2):165-71. Review.</citation>
    <PMID>3294450</PMID>
  </reference>
  <reference>
    <citation>Armon MP, Wenham PW, Whitaker SC, Gregson RH, Hopkinson BR. Common iliac artery aneurysms in patients with abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 1998 Mar;15(3):255-7.</citation>
    <PMID>9587341</PMID>
  </reference>
  <reference>
    <citation>Hobo R, Sybrandy JE, Harris PL, Buth J; EUROSTAR Collaborators. Endovascular repair of abdominal aortic aneurysms with concomitant common iliac artery aneurysm: outcome analysis of the EUROSTAR Experience. J Endovasc Ther. 2008 Feb;15(1):12-22. doi: 10.1583/07-2217.1.</citation>
    <PMID>18254666</PMID>
  </reference>
  <reference>
    <citation>Timaran CH, Lipsitz EC, Veith FJ, Chuter T, Greenberg RK, Ohki T, Nolte LA, Snyder SA; Zenith Investigators. Endovascular aortic aneurysm repair with the Zenith endograft in patients with ectatic iliac arteries. Ann Vasc Surg. 2005 Mar;19(2):161-6.</citation>
    <PMID>15776309</PMID>
  </reference>
  <reference>
    <citation>Ziegler P, Avgerinos ED, Umscheid T, Perdikides T, Erz K, Stelter WJ. Branched iliac bifurcation: 6 years experience with endovascular preservation of internal iliac artery flow. J Vasc Surg. 2007 Aug;46(2):204-10. Epub 2007 Jun 27.</citation>
    <PMID>17600664</PMID>
  </reference>
  <reference>
    <citation>Abraham CZ, Reilly LM, Schneider DB, Dwyer S, Sawhney R, Messina LM, Chuter TA. A modular multi-branched system for endovascular repair of bilateral common iliac artery aneurysms. J Endovasc Ther. 2003 Apr;10(2):203-7. Review.</citation>
    <PMID>12877600</PMID>
  </reference>
  <reference>
    <citation>Su WT, Stone DH, Lamparello PJ, Rockman CB. Gluteal compartment syndrome following elective unilateral internal iliac artery embolization before endovascular abdominal aortic aneurysm repair. J Vasc Surg. 2004 Mar;39(3):672-5.</citation>
    <PMID>14981467</PMID>
  </reference>
  <reference>
    <citation>Razavi MK, DeGroot M, Olcott C 3rd, Sze D, Kee S, Semba CP, Dake MD. Internal iliac artery embolization in the stent-graft treatment of aortoiliac aneurysms: analysis of outcomes and complications. J Vasc Interv Radiol. 2000 May;11(5):561-6.</citation>
    <PMID>10834485</PMID>
  </reference>
  <reference>
    <citation>Karch LA, Hodgson KJ, Mattos MA, Bohannon WT, Ramsey DE, McLafferty RB. Adverse consequences of internal iliac artery occlusion during endovascular repair of abdominal aortic aneurysms. J Vasc Surg. 2000 Oct;32(4):676-83.</citation>
    <PMID>11013030</PMID>
  </reference>
  <reference>
    <citation>Yano OJ, Morrissey N, Eisen L, Faries PL, Soundararajan K, Wan S, Teodorescu V, Kerstein M, Hollier LH, Marin ML. Intentional internal iliac artery occlusion to facilitate endovascular repair of aortoiliac aneurysms. J Vasc Surg. 2001 Aug;34(2):204-11.</citation>
    <PMID>11496269</PMID>
  </reference>
  <reference>
    <citation>Mehta M, Veith FJ, Ohki T, Cynamon J, Goldstein K, Suggs WD, Wain RA, Chang DW, Friedman SG, Scher LA, Lipsitz EC. Unilateral and bilateral hypogastric artery interruption during aortoiliac aneurysm repair in 154 patients: a relatively innocuous procedure. J Vasc Surg. 2001 Feb;33(2 Suppl):S27-32.</citation>
    <PMID>11174809</PMID>
  </reference>
  <reference>
    <citation>Bratby MJ, Munneke GM, Belli AM, Loosemore TM, Loftus I, Thompson MM, Morgan RA. How safe is bilateral internal iliac artery embolization prior to EVAR? Cardiovasc Intervent Radiol. 2008 Mar-Apr;31(2):246-53. Epub 2007 Oct 24.</citation>
    <PMID>17957407</PMID>
  </reference>
  <reference>
    <citation>Rayt HS, Bown MJ, Lambert KV, Fishwick NG, McCarthy MJ, London NJ, Sayers RD. Buttock claudication and erectile dysfunction after internal iliac artery embolization in patients prior to endovascular aortic aneurysm repair. Cardiovasc Intervent Radiol. 2008 Jul-Aug;31(4):728-34. doi: 10.1007/s00270-008-9319-3. Epub 2008 Mar 13. Review.</citation>
    <PMID>18338212</PMID>
  </reference>
  <reference>
    <citation>Torsello G, Schönefeld E, Osada N, Austermann M, Pennekamp C, Donas KP. Endovascular treatment of common iliac artery aneurysms using the bell-bottom technique: long-term results. J Endovasc Ther. 2010 Aug;17(4):504-9. doi: 10.1583/10-3112.1.</citation>
    <PMID>20681766</PMID>
  </reference>
  <reference>
    <citation>Karthikesalingam A, Hinchliffe RJ, Holt PJ, Boyle JR, Loftus IM, Thompson MM. Endovascular aneurysm repair with preservation of the internal iliac artery using the iliac branch graft device. Eur J Vasc Endovasc Surg. 2010 Mar;39(3):285-94. doi: 10.1016/j.ejvs.2009.11.018. Epub 2009 Dec 3. Review.</citation>
    <PMID>19962329</PMID>
  </reference>
  <reference>
    <citation>Parlani G, Verzini F, De Rango P, Brambilla D, Coscarella C, Ferrer C, Cao P. Long-term results of iliac aneurysm repair with iliac branched endograft: a 5-year experience on 100 consecutive cases. Eur J Vasc Endovasc Surg. 2012 Mar;43(3):287-92. doi: 10.1016/j.ejvs.2011.12.011. Epub 2012 Jan 10.</citation>
    <PMID>22240335</PMID>
  </reference>
  <reference>
    <citation>Verzini F, Parlani G, Romano L, De Rango P, Panuccio G, Cao P. Endovascular treatment of iliac aneurysm: Concurrent comparison of side branch endograft versus hypogastric exclusion. J Vasc Surg. 2009 May;49(5):1154-61. doi: 10.1016/j.jvs.2008.11.100.</citation>
    <PMID>19394544</PMID>
  </reference>
  <reference>
    <citation>Verhoeven EL, Oikonomou K, Möhner B, Renner H, Ritter W; European C3 Global Registry Participants. First experience with the new repositionable C3 excluder stent-graft. J Cardiovasc Surg (Torino). 2011 Oct;52(5):637-42. Epub 2011 Jul 29.</citation>
    <PMID>21799475</PMID>
  </reference>
  <reference>
    <citation>Bastos Gonçalves F, Jairam A, Voûte MT, Moelker AD, Rouwet EV, ten Raa S, Hendriks JM, Verhagen HJ. Clinical outcome and morphologic analysis after endovascular aneurysm repair using the Excluder endograft. J Vasc Surg. 2012 Oct;56(4):920-8. doi: 10.1016/j.jvs.2012.03.263. Epub 2012 Jun 15.</citation>
    <PMID>22703975</PMID>
  </reference>
  <reference>
    <citation>Pratesi C, Piffaretti G, Pratesi G, Castelli P; ITalian Excluder Registry Investigators. ITalian Excluder Registry and results of Gore Excluder endograft for the treatment of elective infrarenal abdominal aortic aneurysms. J Vasc Surg. 2014 Jan;59(1):52-7.e1. doi: 10.1016/j.jvs.2013.06.067. Epub 2013 Sep 20.</citation>
    <PMID>24055513</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2015</study_first_submitted>
  <study_first_submitted_qc>January 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rijnstate Hospital</investigator_affiliation>
    <investigator_full_name>Michel Reijnen</investigator_full_name>
    <investigator_title>Vascular surgeon</investigator_title>
  </responsible_party>
  <keyword>Vascular diseases</keyword>
  <keyword>Aneurysm</keyword>
  <keyword>Treatment Efficacy</keyword>
  <keyword>Medical device</keyword>
  <keyword>Population Register</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
    <mesh_term>Iliac Aneurysm</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

